The lipid metabolism modulators market is projected to grow from USD 41.2 billion in 2026 to USD 73.8 billion by 2036, expanding at a CAGR of 6.0%. Growth is supported by the rising prevalence of dyslipidemia, increasing cardiovascular risk, broader lipid screening, and sustained demand for long-term cholesterol management. Pharmacological lipid control remains central to cardiovascular risk...